• Figure 1.

    Hypothetical framework for the pathogenesis of pre-eclampsia. Placental dysfunction triggered by poorly understood mechanisms—including genetic, immunologic, and environmental—plays an early and primary role in the development of pre-eclampsia. Placental dysfunction leads to aberrant production of antiangiogenic factors (soluble fms-like tyrosine kinase 1 and soluble endoglin), contributing to systemic endothelial cell dysfunction. Endothelial dysfunction, in turn, results in the systemic manifestations of pre-eclampsia.

  • 1.

    World Health Organization. World Health Report: Make Every Mother and Child Count. Geneva, World Health Organization, 2005.

  • 2.

    Maynard SE, et al.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649658.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Levine RJ, et al.. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672683.

  • 4.

    Chaiworapongsa T, et al.. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190:15411547; discussion 1547–1550.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Robinson CJ, et al.. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195:255259.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Venkatesha S, et al.. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642649.

  • 7.

    Levine RJ, et al.. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:9921005.

  • 8.

    Gilbert JS, et al.. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 2009; 53:399403.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Wolf M, et al.. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005; 193:1622.

  • 10.

    Maynard SE, et al.. Soluble fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57:1R7R.

  • 11.

    Powers RW, et al.. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PloS One 2010; 5:e13263.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Koga K, et al.. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010; 94:305308.

  • 13.

    Kanter D, et al.. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010; 202:184.

  • 14.

    Bdolah Y, et al.. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006; 194:239245.

  • 15.

    Levine RJ, et al.. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006; 194:10341041.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Jeyabalan A, et al.. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens 2008; 21:943947.

  • 17.

    Herse F, et al.. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age matched case study. Hypertension 2009; 53:393398.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Powers RW, et al.. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193:185191.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Levine RJ, et al.. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293:7785.

  • 20.

    Buhimschi CS, et al.. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005; 192:734741.

  • 21.

    Giguere Y, et al.. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010: 56:361375.

  • 22.

    Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension 2009; 53:747748.

  • 23.

    Conde-Agudelo A, et al.. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104:13671391.

  • 24.

    Moore Simas TA et al.. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197:244.

  • 25.

    Kusanovic JP, et al.. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22:10211038.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Lim JH, et al.. Effective prediction of preeclampsia by a combined ratio of angiogenesis related factors. Obstet Gynecol 2008; 111:14031409.

  • 27.

    Shan HY, et al.. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis 2008; 51:10291032.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Young B, et al.. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010; 23:366370.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Hladunewich MA, et al.. Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nat Rev Nephrol2009; 5:658662.

  • 30.

    Li Z, et al.. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50:686692.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Suzuki H, et al.. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009; 54:11291135.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Kumasawa K, et al.. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci 2011; 108:14511455.

Antiangiogenic Factors and Pre-eclampsia

Sharon E. Maynard
Search for other papers by Sharon E. Maynard in
Current site
Google Scholar
PubMed
Close
Restricted access
Save